Ceryx Medical has announced the successful closure of a new funding round, bringing the company’s total raised to US$15 million, with the new investment intended to accelerate development of a permanent, physiologically responsive pacemaker designed to provide long-term support for patients with chronic heart failure.
The investment marks a major milestone in Ceryx’s mission to revolutionise cardiac care with intelligent, adaptive pacing technology, the company says in a press release.
Ceryx’s lead product—a temporary cardiac pacing device—is currently undergoing clinical evaluation. Early results from the ongoing study are encouraging, showing the potential to significantly enhance patient recovery following cardiac surgery, the press release adds.
The latest round of funding will accelerate development of the permanent, physiologically responsive pacemaker which is designed to provide long-term support for patients with chronic heart failure. Unlike conventional pacemakers, Ceryx’s technology mimics the body’s natural modulation of the heart to deliver real-time, biomimetic pacing, offering a more natural and effective treatment option.
“This investment is a strong endorsement of our team, technology, and vision,” said Stuart Plant, chief executive officer of Ceryx Medical. “The early clinical data from our temporary device have given us real momentum, and with this funding, we’re excited to advance our permanent pacing platform—an innovation that could redefine how heart failure is treated.”
The round was supported by leading investors including BGF, Parkwalk Advisors, Development Bank of Wales (DBW), and BBI, all of whom share Ceryx’s vision for a future where heart failure care is enhanced by intelligent bioelectronic systems.
Ceryx Medical has been spun out of research from the Universities of Bristol and Bath in the UK, and Auckland in New Zealand.
